<html>
 <head>
  <title>My Report</title>
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet" />
  <style>
  body {
    width: 8in;
    font-family: Roboto, sans-serif;
    line-height: 1.41;
  }
  div[data-hindcite-references] > div {
    padding-bottom: 1em;
  }
  </style>
 </head>
 <body>
  <div>
   <h2>Introduction</h2>
   <p contenteditable='true'>
   The tumor suppressor p53 plays an important role in the regulation of cell-cycle,
   apoptosis, DNA repair, cellular senescence, and autophagy
   <span data-hindcite-cite='true' id='test-target-1'>(<a data-hindcite-key='PMID20066118' href='#PMID20066118'>1</a>)</span>.
   Accordingly, TP53 mutations and dysfunction are importantly involved in carcinogenesis
   due to the disturbance of these biologic processes it functions in.
   In fact, TP53 mutations occur in more than half of all human cancer cases
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID1905840' href='#PMID1905840'>2</a>]</span>
   and are independent markers of poor prognosis in a variety of cancers
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID27880943' href='#PMID27880943'>3</a>]</span>.
   p53 also plays an important role in immune regulation, e.g.,
   the control of immune responses to infection, autoimmunity, and cancer
   <span data-hindcite-cite='true' id='test-target-2'>[<a data-hindcite-key='PMID27667712' href='#PMID27667712'>4</a>]</span>.
   p53 functions in immunity by induction of apoptosis, removal of apoptotic cells,
   antiviral defense, induction of type I IFN, enhanced pathogen recognition, cytokine production,
   and immune checkpoint regulation
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID27667712' href='#PMID27667712'>4</a>]</span>.
   Several studies have explored the association of p53 and tumor immune regulation
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID26228128' href='#PMID26228128'>5</a>,
    <a data-hindcite-key='PMID21764762' href='#PMID21764762'>6</a>,
    <a data-hindcite-key='PMID20066118' href='#PMID20066118'>7</a>,
    <a data-hindcite-key='PMID28280037' href='#PMID28280037'>8</a>]</span>.
   For example, the p53 activation in the tumor microenvironment (TME) might overcome
   tumor immune suppression and enhance antitumor immunity
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID28280037' href='#PMID28280037'>8</a>]</span>.
   p53 could transactivate many tumor immunosuppressive genes such as PD-L1, VISTA, and FOXP3
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID26228128' href='#PMID26228128'>5</a>]</span>.
   p53 functioned in both tumor suppression and anticancer immunosurveillance via regulation of VISTA
   <span data-hindcite-cite='true'>[<a data-hindcite-key='PMID26228128' href='#PMID26228128'>5</a>]</span>.
  </div>
  <div>
   <h2>References</h2>
   <div id='hindcite-references'>
    <div data-hindcite-ref='true' id='PMID20066118'><span>1.</span> Zilfou J. T., Lowe S. W.
        Tumor suppressive functions of p53. Cold Spring Harbor Perspectives in Biology. 2009;1(5)
        <a href='https://dx.doi.org/10.1101/cshperspect.a001883.a001883'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/20066118'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID1905840'><span>2.</span> Hollstein M., Sidransky D., Vogelstein B., Harris C. C.
        p53 Mutations in human cancers. Science. 1991;253(5015):49–53.
        <a href='https://dx.doi.org/10.1126/science.1905840'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/1905840'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID27880943'><span>3.</span> Wang X., Sun Q.
        TP53 mutations, expression and interaction networks in human cancers. Oncotarget . 2017;8(1):624–643.
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/27880943'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID27667712'><span>4.</span> Muñoz-Fontela C., Mandinova A., Aaronson S. A., Lee S. W.
        Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nature Reviews Immunology. 2016;16(12):741–750.
        <a href='https://dx.doi.org/10.1038/nri.2016.99'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/27667712'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID26228128'><span>5.</span> Zitvogel L., Kroemer G. CANCER.
        A p53-regulated immune checkpoint relevant to cancer. Science. 2015;349(6247):476–477.
        <a href='https://dx.doi.org/10.1126/science.aac8475'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/26228128'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID21764762'><span>6.</span> Textor S., Fiegler N., Arnold A., Porgador A., Hofmann T. G., Cerwenka A.
        Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Research. 2011;71(18):5998–6009.
        <a href='https://dx.doi.org/10.1158/0008-5472.CAN-10-3211'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/21764762'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID22673234'><span>7.</span> Shatz M., Menendez D., Resnick M. A.
        The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Research. 2012;72(16):3949–3957.
        <a href='https://dx.doi.org/10.1158/0008-5472.CAN-11-4134'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/22673234'>pubmed</a></div>
    <div data-hindcite-ref='true' id='PMID28280037'><span>8.</span> Guo G., Yu M., Xiao W., Celis E., Cui Y.
        Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Research. 2012;77(9):2292–2305.
        <a href='https://dx.doi.org/10.1158/0008-5472.CAN-16-2832'>doi</a>
        <a href='https://www.ncbi.nlm.nih.gov/pubmed/28280037'>pubmed</a></div>
   </div>
  </div>
 </body>
</html>
